HP-5000 Emerging Drug Insight and Market Forecast - 2032

“HP-5000 Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about HP-5000 for knee osteoarthritis (OA) in the seven major markets. A detailed picture of the HP-5000 for knee osteoarthritis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the HP-5000 for knee osteoarthritis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the HP-5000 market forecast analysis for knee osteoarthritis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in knee osteoarthritis.

Drug Summary

HP-5000 (diclofenac sodium) is a transdermal, pain relief and anti-inflammatory patch. The Phase II of the clinical trial was completed in November 2019. The study results suggested that the investigational product was efficacious in the primary endpoint. The mechanism of action of diclofenac, like that of other NSAIDs, is not entirely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2). It is a potent inhibitor of prostaglandin synthesis in vitro. The product is a transdermal formulation developed using Hisamitsu's TDDS (Transdermal Drug Delivery System) technology. The company aims to submit an NDA in the US by 2023. Noven Pharmaceuticals is working collaboratively with its parent company, Hisamitsu; Noven is the US platform for Hisamitsu.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the HP-5000 description, mechanism of action, dosage and administration, research and development activities in knee osteoarthritis.
• Elaborated details on HP-5000 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the HP-5000 research and development activities in knee osteoarthritis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around HP-5000.
• The report contains forecasted sales of HP-5000 for knee osteoarthritis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for knee osteoarthritis.
• The report also features the SWOT analysis with analyst views for HP-5000 in knee osteoarthritis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HP-5000 Analytical Perspective

In-depth HP-5000 Market Assessment

This report provides a detailed market assessment of HP-5000 for knee osteoarthritis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

HP-5000 Clinical Assessment

The report provides the clinical trials information of HP-5000 for knee osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for knee osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HP-5000 dominance.
• Other emerging products for knee osteoarthritis are expected to give tough market competition to HP-5000 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HP-5000 in knee osteoarthritis.
• Our in-depth analysis of the forecasted sales data of HP-5000 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the HP-5000 in knee osteoarthritis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of HP-5000?
• What is the clinical trial status of the study related to HP-5000 in knee osteoarthritis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HP-5000 development?
• What are the key designations that have been granted to HP-5000 for knee osteoarthritis?
• What is the forecasted market scenario of HP-5000 for knee osteoarthritis?
• What are the forecasted sales of HP-5000 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to HP-5000 for knee osteoarthritis?
• Which are the late-stage emerging therapies under development for the treatment of knee osteoarthritis?